Ubiqui Dx
Ubiqui Dx provides an ultra-fast, dual-capacity point-of-care diagnostic platform that performs both immunoassays and nucleic acid tests in under five minutes with zeptomolar sensitivity. Its patented microfluidic sieve and detector enables lab-grade testing in decentralized settings like emergency rooms, operating rooms, and doctor’s offices. The platform’s first application targets intraoperative parathyroid hormone measurement during parathyroid surgery.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Diagnostic testing remains largely centralized in laboratories, forcing critical clinical decisions in the OR, ER, ICU, and doctor’s offices to wait hours for results. Sensitive, fast, and inexpensive diagnostics have not reached the bedside, limiting timely medical decisions and increasing overall healthcare costs.
Solution
Ubiqui Dx offers an ultra-fast, dual-capacity point-of-care platform that performs both immunoassays and nucleic acid detection in under five minutes with zeptomolar sensitivity and a 7+ log dynamic range. The patented Microfluidic Sieve & Detector uses a polymer membrane with half a million 8-µm pores as Brownian affinity traps, sieving 200 µL in about a minute and detecting single molecules. The system delivers results in a sieve-detect-analyze workflow, achieving sensitivity comparable to core-lab digital immunoassays and PCR while operating at the point of care. This enables faster, more precise medical decisions and lower healthcare costs by moving testing out of central labs and into decentralized settings.
Target Audience
Primary users are clinicians in emergency rooms, operating rooms, ICUs, and doctor’s offices who need rapid, lab-grade diagnostic results at the point of care, with the initial application targeting parathyroid surgeons measuring intraoperative parathyroid hormone.
Features
- Dual-capacity testing: performs both immunoassays and nucleic acid (RNA/DNA) detection on a single platform
- Zeptomolar sensitivity (10⁻²¹ M) with a 7+ order-of-magnitude dynamic range and ≤15% CV
- Results in under 5 minutes, benchmarked 25× faster than PCR for equivalent nucleic-acid sensitivity
- Patented microfluidic sieve with 500,000 8-µm pores acting as Brownian affinity traps for single-molecule detection
- Sensitivity scales linearly with sample volume, enabling up to ~10× more sensitivity by increasing volume
- Low-cost, easy-to-use design intended for POC and home settings, not just central labs